search
Back to results

fMRI Study Examining Effects of D-cycloserine in Specific Phobia

Primary Purpose

Phobias

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
D-cycloserine
Placebo
Sponsored by
University of Kansas Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Phobias

Eligibility Criteria

18 Years - 55 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Right-handed
  • Adults between 18 and 55 years of age
  • Subjects in the phobic group will additionally meet diagnostic (DSM-IV) criteria for spider phobia.
  • Individuals of both genders and all races will be included

Exclusion Criteria:

  • Women who are breastfeeding or pregnant
  • Individuals with medical conditions unsuitable for MR scanning
  • Individuals reporting a history of epilepsy or seizures
  • Individuals reporting an allergy to cycloserine
  • Individuals diagnosed with asthma or who report previous anaphylactic reaction to insect stings/bites, medication, food, or other material and/or event
  • Individuals reporting present or past diagnosis of a developmental disorder, neurological disorder, or head injury *Individuals found to have Axis I psychopathology as defined by the DSM-IV (other than spider phobia)
  • Individuals currently taking any psychotropic medication

Sites / Locations

  • University of Kansas Medical Center, Hoglund Brain Imaging Center

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Placebo Comparator

Active Comparator

Placebo Comparator

Experimental

Arm Label

Non-Phobic Control - Placebo

Non-Phobic Control - DCS

Spider-phobic Placebo

Spider-phobic DCS

Arm Description

Participants without phobia will be given one placebo administration.

Participants without phobia will be given one D-cycloserine (DCS) administration of 100mg.

Participants with phobia will be given one placebo administration.

Participants with phobia will be given one D-cycloserine (DCS) administration of 100mg.

Outcomes

Primary Outcome Measures

fMRI Brain Activations During Symptom Provocation
Regions of interest (ROIs) were specified based on previous research and included amygdala, insula, dorsal anterior cingulate cortex (ACC), dorsolateral PFC (dlPFC), and hippocampus. Multiple regression analyses were used to examine differences in response between experimental conditions (spider versus butterfly images). For significant clusters of activation within ROIs, the average max percent signal change is reported. For other regions, the average max percent signal change is reported within a sphere centered at coordinates identified via previous research.

Secondary Outcome Measures

Cognitive Functioning Measured Using the Wechsler Memory Scale III (Logical Memory and Faces Subtests)
This scale measures the learning and memory of functioning adults. Logical Memory I and II and Faces I and II subtests were administered to participants. The tasks measure verbal and visual memory, respectively. Scoring is based on the number of story details or faces correctly recalled during immediate (Logical Memory I, Faces I) and 30 minute delayed (Logical Memory II, Faces II) conditions. Total score ranges from 0-75 on Logical Memory I, 0-50 on Logical Memory II, 0-48 on Faces I, and 0-48 on Faces II. For all subtests, higher scores indicate better memory performance.
Cognitive Functioning Measured Using the Rey-Osterrieth Complex Figure Test (RCFT)
The RCFT assesses the a person's ability to use cues to retrieve information. The test measures visuospatial construction and memory. A person is asked to draw a figure. The figure is broken down into 18 elements. The score is based on their presence, completeness, and correct placement. Each element is scored from 0-2. The Copy, Immediate, and Delay results are scored on a 36 point scale. The higher the score, the better the person performed on the test with a 0 being the minimum and 36 being the maximum score. The organization score is scored according to whether the participant drew five cohesive units of the figure together, for a range of 0-6 and a higher score indicating better organizational performance.
Cognitive Functioning Measured Using the Iowa Gambling Test
This test measures a person's emotional decision making. Participants are presented with virtual decks of cards on a computer. Participants are told that each card they draw will "win" them game money. However, sometimes cards result in "losing" game money. The task includes 100 trials and the total score represents the number of cards drawn from "bad" decks as compared to "good" or safe decks. Thus, the score ranges from -100 to +100, with higher sores representing better performance.
Cognitive Functioning Measured Using the Wisconsin Card Sorting Task
The Wisconsin Card Sorting Task measures executive functioning and cognitive flexibility. The task uses a deck of 64 cards that the participant must sort according to specified rules. The test is stopped when when six sequences of 10 correct responses have been achieved, or after the deck has been completed twice, which provides a cumulative total of 128 trials. We report the number of errors on the task, which has a range of 0 -128, with a higher score representing worse performance.

Full Information

First Posted
December 27, 2007
Last Updated
June 1, 2017
Sponsor
University of Kansas Medical Center
Collaborators
American Psychological Foundation, American Psychological Association
search

1. Study Identification

Unique Protocol Identification Number
NCT00591825
Brief Title
fMRI Study Examining Effects of D-cycloserine in Specific Phobia
Official Title
An fMRI Study Investigating the Effects of Acute D-cycloserine Administration on Brain Activations and Cognitive Functioning in Spider Phobia.
Study Type
Interventional

2. Study Status

Record Verification Date
June 2017
Overall Recruitment Status
Completed
Study Start Date
March 2006 (undefined)
Primary Completion Date
December 2012 (Actual)
Study Completion Date
December 2012 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Kansas Medical Center
Collaborators
American Psychological Foundation, American Psychological Association

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The research team hopes to use brain imaging and mental testing to learn more about specific phobias and the treatment of phobia. When given directly prior to therapy sessions, D-cycloserine has been shown to enhance the effects of therapy. This study hopes to identify reasons why D-cycloserine has this effect by measuring brain activity.
Detailed Description
Exposure and Response Prevention (ERP) therapy has become the treatment of choice for specific phobias. ERP involves systematic and repeated exposure to a feared or anxiety-provoking stimulus, leading to habituation and extinction of the fear response. Animal models of fear extinction have shown that acute administration of D-cycloserine (DCS) prior to exposure to a feared stimulus enhances extinction of that fear. A recent study in human subjects with height phobia (a specific phobia) has also demonstrated that DCS facilitates the effects of ERP therapy. Current theories postulate that DCS facilitates fear extinction by enhancing the learning process and increasing consolidation of memories, but the neural mechanisms underlying this process are not understood. The proposed research aims to elucidate these mechanisms by using fMRI to measure brain activation during 1) symptom provocation and verbal learning two hours post-medication, and 2)repeated symptom provocation and verbal recognition one week post-medication. This research will also examine the effects of DCS on cognitive functioning using neuropsychological testing both two house and one week post-medication.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Phobias

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
54 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Non-Phobic Control - Placebo
Arm Type
Placebo Comparator
Arm Description
Participants without phobia will be given one placebo administration.
Arm Title
Non-Phobic Control - DCS
Arm Type
Active Comparator
Arm Description
Participants without phobia will be given one D-cycloserine (DCS) administration of 100mg.
Arm Title
Spider-phobic Placebo
Arm Type
Placebo Comparator
Arm Description
Participants with phobia will be given one placebo administration.
Arm Title
Spider-phobic DCS
Arm Type
Experimental
Arm Description
Participants with phobia will be given one D-cycloserine (DCS) administration of 100mg.
Intervention Type
Drug
Intervention Name(s)
D-cycloserine
Other Intervention Name(s)
Cycloserine
Intervention Description
D-cycloserine
Intervention Type
Drug
Intervention Name(s)
Placebo
Other Intervention Name(s)
Sugar pill
Intervention Description
Placebo
Primary Outcome Measure Information:
Title
fMRI Brain Activations During Symptom Provocation
Description
Regions of interest (ROIs) were specified based on previous research and included amygdala, insula, dorsal anterior cingulate cortex (ACC), dorsolateral PFC (dlPFC), and hippocampus. Multiple regression analyses were used to examine differences in response between experimental conditions (spider versus butterfly images). For significant clusters of activation within ROIs, the average max percent signal change is reported. For other regions, the average max percent signal change is reported within a sphere centered at coordinates identified via previous research.
Time Frame
2 Weeks
Secondary Outcome Measure Information:
Title
Cognitive Functioning Measured Using the Wechsler Memory Scale III (Logical Memory and Faces Subtests)
Description
This scale measures the learning and memory of functioning adults. Logical Memory I and II and Faces I and II subtests were administered to participants. The tasks measure verbal and visual memory, respectively. Scoring is based on the number of story details or faces correctly recalled during immediate (Logical Memory I, Faces I) and 30 minute delayed (Logical Memory II, Faces II) conditions. Total score ranges from 0-75 on Logical Memory I, 0-50 on Logical Memory II, 0-48 on Faces I, and 0-48 on Faces II. For all subtests, higher scores indicate better memory performance.
Time Frame
2 Weeks
Title
Cognitive Functioning Measured Using the Rey-Osterrieth Complex Figure Test (RCFT)
Description
The RCFT assesses the a person's ability to use cues to retrieve information. The test measures visuospatial construction and memory. A person is asked to draw a figure. The figure is broken down into 18 elements. The score is based on their presence, completeness, and correct placement. Each element is scored from 0-2. The Copy, Immediate, and Delay results are scored on a 36 point scale. The higher the score, the better the person performed on the test with a 0 being the minimum and 36 being the maximum score. The organization score is scored according to whether the participant drew five cohesive units of the figure together, for a range of 0-6 and a higher score indicating better organizational performance.
Time Frame
2 weeks
Title
Cognitive Functioning Measured Using the Iowa Gambling Test
Description
This test measures a person's emotional decision making. Participants are presented with virtual decks of cards on a computer. Participants are told that each card they draw will "win" them game money. However, sometimes cards result in "losing" game money. The task includes 100 trials and the total score represents the number of cards drawn from "bad" decks as compared to "good" or safe decks. Thus, the score ranges from -100 to +100, with higher sores representing better performance.
Time Frame
2 weeks
Title
Cognitive Functioning Measured Using the Wisconsin Card Sorting Task
Description
The Wisconsin Card Sorting Task measures executive functioning and cognitive flexibility. The task uses a deck of 64 cards that the participant must sort according to specified rules. The test is stopped when when six sequences of 10 correct responses have been achieved, or after the deck has been completed twice, which provides a cumulative total of 128 trials. We report the number of errors on the task, which has a range of 0 -128, with a higher score representing worse performance.
Time Frame
2 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Right-handed Adults between 18 and 55 years of age Subjects in the phobic group will additionally meet diagnostic (DSM-IV) criteria for spider phobia. Individuals of both genders and all races will be included Exclusion Criteria: Women who are breastfeeding or pregnant Individuals with medical conditions unsuitable for MR scanning Individuals reporting a history of epilepsy or seizures Individuals reporting an allergy to cycloserine Individuals diagnosed with asthma or who report previous anaphylactic reaction to insect stings/bites, medication, food, or other material and/or event Individuals reporting present or past diagnosis of a developmental disorder, neurological disorder, or head injury *Individuals found to have Axis I psychopathology as defined by the DSM-IV (other than spider phobia) Individuals currently taking any psychotropic medication
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Cary Savage, PhD
Organizational Affiliation
University of Kansas Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Kansas Medical Center, Hoglund Brain Imaging Center
City
Kansas City
State/Province
Kansas
ZIP/Postal Code
66160
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

fMRI Study Examining Effects of D-cycloserine in Specific Phobia

We'll reach out to this number within 24 hrs